课题基金 / 基金详情

项目摘要

项目成果

KEITH R SOLOMON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Although prostate cancer (PCa) remains one of the leading causes of death from cancer in American men, the specific nutritional factors affecting disease progression and their potential mechanisms of action are largely unknown. This project tests the hypothesis that serum cholesterol and membrane cholesterol, through their roles in regulating the size and complexity of lipid raft membrane domains, affect parameters of PCa progression in vitro and in vivo. This application responds to the RFA by directly evaluating the effect of dietary cholesterol on prostate tumor progression and the ability of membrane cholesterol to regulate the ErbB/PI3K/Akt anti-apoptotic signaling axis, a critical cell survival pathways operating constitutively in prostate tumor cells. In these studies we will examine the role of cholesterol-rich lipid raft signaling complexes in orchestrating and regulating ErbB receptor family distribution, dimerization and activation, PI3 kinase distribution and activation, and Akt isoform distribution and activation. We will determine the effect of membrane cholesterol modulation on these signaling molecules and on prostate tumor cell survival. We will study the effect of dietary cholesterol on prostate tumor progression in vivo using a murine model of human tumor cell progression, as well as two autochthonous PCa mouse models. We will test whether high levels of dietary cholesterol cause PIN to convert to frank cancer, to accelerate the growth of prostate tumors and to promote metastasis. We will determine whether high levels of dietary cholesterol cause cholesterol accumulation in prostate tumors and affect the form and function of lipid raft domains. These hypothesis driven, mechanistic studies on the role of dietary and membrane cholesterol on PCa disease progression may suggest new therapies for the treatment and management of the disease, such as the use of HMG-CoA reductase inhibitor drugs or the use of low cholesterol diets. Further, these studies also have the potential to identify new drug targets.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
Two different PDGF beta-receptor cohorts in human pericytes mediate distinct biological endpoints.
人类周细胞中两个不同的 PDGF β 受体群体介导不同的生物学终点。
DOI: 10.2353/ajpath.2009.080769
发表时间: 2009
期刊: The American journal of pathology
影响因子: --
作者: [Sundberg,Christian, Friman,Tomas, Hecht,LeahE, Kuhl,Christine, Solomon,KeithR]
通讯作者: Solomon,KeithR
DOI: 10.1016/j.ucl.2011.04.001
发表时间: 2011-08
期刊: UROLOGIC CLINICS OF NORTH AMERICA
影响因子: 2.4
作者: [Solomon, Keith R., Freeman, Michael R.]
通讯作者: Freeman, Michael R.
The response of the prostate to circulating cholesterol: activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network.
前列腺对循环胆固醇的反应:激活转录因子 3 (ATF3) 作为胆固醇传感网络中的一个重要节点。
DOI: 10.1371/journal.pone.0039448
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者: [Kim,Jayoung, DiVizio,Dolores, Kim,Taek-Kyun, Kim,Jonghwan, Kim,Minjung, Pelton,Kristine, Clinton,StevenK, Hai,Tsonwin, Hwang,Daehee, Solomon,KeithR, Freeman,MichaelR]
通讯作者: Freeman,MichaelR
The Harvard Urologic Research Cener
  • 批准号:
    7500541
  • 项目类别:
  • 资助金额:
    $17.16万
  • 财政年份:
    2007
  • 负责人:
    KEITH R SOLOMON
  • 依托单位:
PROTEOMICS CORE
  • 批准号:
    7661993
  • 项目类别:
  • 资助金额:
    $16.99万
  • 财政年份:
    2006
  • 负责人:
    KEITH R SOLOMON
  • 依托单位:
PROTEOMICS CORE
  • 批准号:
    7661885
  • 项目类别:
  • 资助金额:
    $17.51万
  • 财政年份:
    2005
  • 负责人:
    KEITH R SOLOMON
  • 依托单位:
Cholesterol and Prostate Cancer Progression
  • 批准号:
    6617464
  • 项目类别:
  • 资助金额:
    $28.57万
  • 财政年份:
    2003
  • 负责人:
    KEITH R SOLOMON
  • 依托单位:
海外基金